Supplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Authors:
- Rebecca MazahrehRMRebecca Mazahreh
- Marsha L. MasonMMMarsha L. Mason
- John J. GosinkJGJohn J. Gosink
- Devra J. OlsonDODevra J. Olson
- Robert ThurmanRTRobert Thurman
- Christopher HaleCHChristopher Hale
- Lori WestendorfLWLori Westendorf
- Thomas A. PiresTPThomas A. Pires
- Christopher I. LeiskeCLChristopher I. Leiske
- Markus CarlsonMCMarkus Carlson
- Liem T. NguyenLNLiem T. Nguyen
- Julia H. CochranJCJulia H. Cochran
Open Access
- 27 November 2025
- other
- Published by American Association for Cancer Research (AACR)